Article: Alzheimer Disease: A Life-Limiting Disease With a Burden of a Terminal Illness.
2023 Volume 13, Issue 6, Page(s) e200208
Abstract: Purpose of review: An estimated 6.5 million Americans live with Alzheimer dementia. Better understanding of advanced stages of Alzheimer disease (AD) and timely monitoring of its preventable complications would translate to improved survival and quality ...
Abstract | Purpose of review: An estimated 6.5 million Americans live with Alzheimer dementia. Better understanding of advanced stages of Alzheimer disease (AD) and timely monitoring of its preventable complications would translate to improved survival and quality of life in this population. Recent findings: In this perspective review, we proposed shifting the narrative to recognizing AD as a chronic life-limiting illness instead of a terminal disease. In support of this view, we discussed the following: (1) the biochemical, cellular (preclinical), and clinical phases of AD; (2) survival after AD; (3) AD therapeutics and potential implications for the population with AD in the advanced stages. Summary: On the bases of the prolonged preclinical phase in AD, promising advances in AD therapeutics and the varying survival after AD, we proposed a new classification for AD and more broadly neurodegenerative disorders to be recognized as chronic |
---|---|
Language | English |
Publishing date | 2023-10-16 |
Publishing country | United States |
Document type | Journal Article ; Review |
ZDB-ID | 2645818-4 |
ISSN | 2163-0933 ; 2163-0402 |
ISSN (online) | 2163-0933 |
ISSN | 2163-0402 |
DOI | 10.1212/CPJ.0000000000200208 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.